Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Clinical outcomes of a new trifocal intraocular lens with enhanced light energy technology

Poster Details

First Author: B.Bostanci TURKEY

Co Author(s):    A. Karatepe Hashas   E. Tasindi                 

Abstract Details

Purpose:

To evaluate the refractive, visual and contrast sensitivity outcomes with subjective results after implantation of a new trifocal intraocular lens (IOL).

Setting:

Okan University Hospital, Ophthalmology Department, �Ä�°stanbul, Turkey

Methods:

The study included 44 eyes of 22 patients, which received Acrysof IQ Panoptix (�.17 diopter (D) /�.25 D IOL, Alcon Surgical, Inc.) IOL after cataract surgery. Refraction; binocular and monocular corrected and uncorrected distance, intermediate (66 cm) and near (33 cm) visual acuities (VA) and contrast sensitivity was measured at the 3 months postoperative visit. Level of capsule opacification and stabilization of the IOL was noted and photic phenomena (glare, halo, dysphotopsia) were questioned additionally.

Results:

Mean age of the patients was 63.4�Â�±7.1. At the 3rd month visit, mean spherical equivalent was 0.31�Â�±0.20D. Mean uncorrected and corrected monocular distance VA was 0.05�Â�±0.10LogMAR and 0.00�Â�±0.08LogMAR respectively. Mean binocular uncorrected VA was �â�ˆ�’0.04�Â�±0.09LogMAR. Binocular near VA was Jaeger(J)2 or 1 in 95% of the patients whereas, 90% read J2 or 1 in the intermediate distance. Mean contrast sensitivity was between normal limits in mezopic and photopic conditions. Posterior capsule opacification necessitating neodymium:YAG lazer capsulotomy or lens decentration was not observed. Two cases with 1 D or more postoperative cylindrical error reported glare problems.

Conclusions:

The new trifocal IOL design provided stable refractive correction and desirable visual restoration for distant, intermediate and near vision with satisfactory visual quality.

Financial Disclosure:

NONE

Back to Poster listing